Alexandros Chronas BBioMed, MD, Karin Thursky MBBS, BSc, MD, FRACP, FAHMS, FAIDH, Simone Mo BBioMed, MD, Lisa Hall BTech(BiomedSci) (Hons), PhD, Rodney James BMedSci, BMed, MPHTM, FRCPA, Courtney Ierano BPharm(Hons), GradCertPharmPrac, PhD
{"title":"静脉注射阿莫西林-克拉维酸:澳大利亚医院的处方做法","authors":"Alexandros Chronas BBioMed, MD, Karin Thursky MBBS, BSc, MD, FRACP, FAHMS, FAIDH, Simone Mo BBioMed, MD, Lisa Hall BTech(BiomedSci) (Hons), PhD, Rodney James BMedSci, BMed, MPHTM, FRCPA, Courtney Ierano BPharm(Hons), GradCertPharmPrac, PhD","doi":"10.1002/jppr.1930","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Oral amoxicillin-clavulanic acid, a broad-spectrum antimicrobial and one of the most commonly prescribed antimicrobials in Australia, has demonstrated poor prescribing guideline compliance and appropriateness. This may have inadvertent impacts on patient care and safety, from adverse drug reactions to antimicrobial resistance. Intravenous (IV) amoxicillin-clavulanic acid was first registered in Australia in 2017, reflecting a subsequent and immediate increase in use. There is a need to assess the quality of such prescribing.</p>\n </section>\n \n <section>\n \n <h3> Aim</h3>\n \n <p>To describe the quality of IV amoxicillin-clavulanic acid prescriptions through assessing guideline compliance and appropriateness of use in Australian hospitals.</p>\n </section>\n \n <section>\n \n <h3> Method</h3>\n \n <p>A retrospective data analysis of IV amoxicillin-clavulanic acid prescriptions from the Hospital National Antimicrobial Prescribing Survey database between 2013 and 2021. The main outcomes measured were guideline compliance and appropriateness. Ethical approval was granted by the Melbourne Health Human Research Ethics Committee (HREC/74195/MH-2022).</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>The proportion of prescriptions for IV amoxicillin-clavulanic acid, compared to all other antimicrobials, increased from 0.02% (2013) to 2.3% (2021). Guideline compliance and appropriateness have overall decreased (by 18.9% and 16.7%, respectively). Over time, national guidelines predominantly replaced local guidelines as the primary guideline source for prescribing. The most common reason for inappropriateness was unnecessarily broad spectrum of activity (39.5%).</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Intravenous amoxicillin-clavulanic acid prescribing continues to increase throughout Australian hospitals, with notable reductions in guideline compliance and appropriateness. Since 2019, the increase in these outcomes coincided with updated national prescribing guidelines, evident by prescribers utilising national over local guidelines. These findings reinforce the concept that antimicrobial stewardship initiatives, including auditing, robust national guidelines and education, are crucial to optimise IV amoxicillin-clavulanic acid prescribing.</p>\n </section>\n </div>","PeriodicalId":16795,"journal":{"name":"Journal of Pharmacy Practice and Research","volume":"54 5","pages":"384-392"},"PeriodicalIF":1.0000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1930","citationCount":"0","resultStr":"{\"title\":\"Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals\",\"authors\":\"Alexandros Chronas BBioMed, MD, Karin Thursky MBBS, BSc, MD, FRACP, FAHMS, FAIDH, Simone Mo BBioMed, MD, Lisa Hall BTech(BiomedSci) (Hons), PhD, Rodney James BMedSci, BMed, MPHTM, FRCPA, Courtney Ierano BPharm(Hons), GradCertPharmPrac, PhD\",\"doi\":\"10.1002/jppr.1930\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> Background</h3>\\n \\n <p>Oral amoxicillin-clavulanic acid, a broad-spectrum antimicrobial and one of the most commonly prescribed antimicrobials in Australia, has demonstrated poor prescribing guideline compliance and appropriateness. This may have inadvertent impacts on patient care and safety, from adverse drug reactions to antimicrobial resistance. Intravenous (IV) amoxicillin-clavulanic acid was first registered in Australia in 2017, reflecting a subsequent and immediate increase in use. There is a need to assess the quality of such prescribing.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Aim</h3>\\n \\n <p>To describe the quality of IV amoxicillin-clavulanic acid prescriptions through assessing guideline compliance and appropriateness of use in Australian hospitals.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Method</h3>\\n \\n <p>A retrospective data analysis of IV amoxicillin-clavulanic acid prescriptions from the Hospital National Antimicrobial Prescribing Survey database between 2013 and 2021. The main outcomes measured were guideline compliance and appropriateness. Ethical approval was granted by the Melbourne Health Human Research Ethics Committee (HREC/74195/MH-2022).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Results</h3>\\n \\n <p>The proportion of prescriptions for IV amoxicillin-clavulanic acid, compared to all other antimicrobials, increased from 0.02% (2013) to 2.3% (2021). Guideline compliance and appropriateness have overall decreased (by 18.9% and 16.7%, respectively). Over time, national guidelines predominantly replaced local guidelines as the primary guideline source for prescribing. The most common reason for inappropriateness was unnecessarily broad spectrum of activity (39.5%).</p>\\n </section>\\n \\n <section>\\n \\n <h3> Conclusion</h3>\\n \\n <p>Intravenous amoxicillin-clavulanic acid prescribing continues to increase throughout Australian hospitals, with notable reductions in guideline compliance and appropriateness. Since 2019, the increase in these outcomes coincided with updated national prescribing guidelines, evident by prescribers utilising national over local guidelines. These findings reinforce the concept that antimicrobial stewardship initiatives, including auditing, robust national guidelines and education, are crucial to optimise IV amoxicillin-clavulanic acid prescribing.</p>\\n </section>\\n </div>\",\"PeriodicalId\":16795,\"journal\":{\"name\":\"Journal of Pharmacy Practice and Research\",\"volume\":\"54 5\",\"pages\":\"384-392\"},\"PeriodicalIF\":1.0000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/jppr.1930\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Pharmacy Practice and Research\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1930\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Pharmacy Practice and Research","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/jppr.1930","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Intravenous amoxicillin-clavulanic acid: prescribing practices in Australian hospitals
Background
Oral amoxicillin-clavulanic acid, a broad-spectrum antimicrobial and one of the most commonly prescribed antimicrobials in Australia, has demonstrated poor prescribing guideline compliance and appropriateness. This may have inadvertent impacts on patient care and safety, from adverse drug reactions to antimicrobial resistance. Intravenous (IV) amoxicillin-clavulanic acid was first registered in Australia in 2017, reflecting a subsequent and immediate increase in use. There is a need to assess the quality of such prescribing.
Aim
To describe the quality of IV amoxicillin-clavulanic acid prescriptions through assessing guideline compliance and appropriateness of use in Australian hospitals.
Method
A retrospective data analysis of IV amoxicillin-clavulanic acid prescriptions from the Hospital National Antimicrobial Prescribing Survey database between 2013 and 2021. The main outcomes measured were guideline compliance and appropriateness. Ethical approval was granted by the Melbourne Health Human Research Ethics Committee (HREC/74195/MH-2022).
Results
The proportion of prescriptions for IV amoxicillin-clavulanic acid, compared to all other antimicrobials, increased from 0.02% (2013) to 2.3% (2021). Guideline compliance and appropriateness have overall decreased (by 18.9% and 16.7%, respectively). Over time, national guidelines predominantly replaced local guidelines as the primary guideline source for prescribing. The most common reason for inappropriateness was unnecessarily broad spectrum of activity (39.5%).
Conclusion
Intravenous amoxicillin-clavulanic acid prescribing continues to increase throughout Australian hospitals, with notable reductions in guideline compliance and appropriateness. Since 2019, the increase in these outcomes coincided with updated national prescribing guidelines, evident by prescribers utilising national over local guidelines. These findings reinforce the concept that antimicrobial stewardship initiatives, including auditing, robust national guidelines and education, are crucial to optimise IV amoxicillin-clavulanic acid prescribing.
期刊介绍:
The purpose of this document is to describe the structure, function and operations of the Journal of Pharmacy Practice and Research, the official journal of the Society of Hospital Pharmacists of Australia (SHPA). It is owned, published by and copyrighted to SHPA. However, the Journal is to some extent unique within SHPA in that it ‘…has complete editorial freedom in terms of content and is not under the direction of the Society or its Council in such matters…’. This statement, originally based on a Role Statement for the Editor-in-Chief 1993, is also based on the definition of ‘editorial independence’ from the World Association of Medical Editors and adopted by the International Committee of Medical Journal Editors.